Khalid AL. Naamani: Efficacy, Safety, and Patient Selection of DOACs in Cirrhosis
Khalid AL. Naamani, Executive Committee Member Ministry of Health Oman, Chairman of The Medical City for Military and Security Services, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
”I’m pleased to share our recent publication: Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice
In this review, we explore the evolving role of direct oral anticoagulants (DOACs) in the management of portal vein thrombosis (PVT) in patients with cirrhosis.
Key highlights:
- Hemostasis in cirrhosis is a complex, rebalanced state rather than a simple bleeding tendency
- DOACs offer a promising alternative to traditional anticoagulants, with convenient fixed dosing and favorable safety profiles
- Evidence suggests comparable – and in some cases superior – recanalization rates versus VKAs, without a significant increase in major or variceal bleeding
- Careful patient selection remains essential, particularly based on liver function (CTP classification), renal status, and transplant candidacy
While current data are encouraging, further prospective studies are still needed, especially in patients with more advanced cirrhosis.
Grateful to my co-authors and collaborators for their valuable contributions to this work.”
Title: Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice
Authors: Khalid M. Al Naamani, Sundus Rizwan, Siham Al Sinani, Bader Al Rawahi, Sheikha AlMa’mari, Mohamed El-Kassas
Read the Full Article on Clinical and Applied Thrombosis/Hemostasis
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 11, 2026, 12:35Danielle Boyle: The Person I Was and the Person I Became After My ITP Diagnosis
-
Apr 11, 2026, 12:29A Self-Regulatory Mechanism of The PolyP-Thrombin-Fibrin Complex – JTH
-
Apr 11, 2026, 12:26A Novel Genetic Mechanism of Caplacizumab Resistance in iTTP – JTH
-
Apr 11, 2026, 12:23Fariba Rafiee: What Happens When You Isolate the Left Atrial Appendage in Patients with Persistent AFib?
-
Apr 11, 2026, 11:59Dilini Christina Ranasinghe: Why Leucoreduction Timing Matters in Transfusion Safety
-
Apr 11, 2026, 11:52Muhammad Bilal: A Quick Visual Guide to the ABO Blood Group System
-
Apr 11, 2026, 11:28Waqar Ahmad Khan: Clinical Features and Management of TTP
-
Apr 10, 2026, 18:22Chris Hillis: Reflections on My Term as President of the Canadian Hematology Society
-
Apr 10, 2026, 17:59Michelle Leona Cecil: Representing Microhealth at The Coalition for Hemophilia B Annual Symposium